Anetoderma: Is It a Sign of Autoimmunity? by Al Buainain, Hessa & Allam, Mohamed
 
Case Rep Dermatol 2009;1:100–104 
DOI: 10.1159/000265699 
Published online: December 22, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
 
 
Dr. Mohamed Allam    Dermatology Department, Al Khor Hospital, Hamad Medical Corporation  
PO Box 3050, Al Khor (Qatar) 
Tel. +974 474 55 11, Fax +974 474 52 53, E-Mail mohamed.allam@hotmail.com 
 
100
   
Anetoderma: Is It a Sign of 
Autoimmunity? 
Hessa Al Buainaina    Mohamed Allamb 
aDermatology Department, Rumailah Hospital, Hamad Medical Corporation, 
Doha, bDermatology Department, Al Khor Hospital, Hamad Medical Corporation, 
Al Khor, Qatar 
 
Key Words 
Anetoderma · Thyroid · Autoimmune thyroiditis · Grave’s disease · Primary 
hypothyroidism 
 
Abstract 
Anetoderma is a rare elastolytic disorder characterized by circumscribed areas of flaccid 
skin due to the loss of elastic tissue in the dermis. Primary anetoderma is frequently 
observed in patients with autoimmune diseases or abnormalities especially with 
antiphospholipid antibodies with or without antiphospholipid syndrome. In this case 
report we discuss a patient with primary anetoderma with positive antithyroid 
peroxidase antibodies, which is consistent with autoimmune thyroiditis. 
 
Case Report 
A 42-year-old Indian male had multiple small circumscribed wrinkled sacs like lesions on the 
shoulders and upper back of 4 months duration (fig. 1). It was not preceded by any inflammatory skin 
lesions. Skin biopsy was taken for histopathological examination and revealed minimal dermal 
perivascular chronic inflammatory cells infiltrate (fig. 2). Elastic stain (Verhoef-Van Gieson) showed 
loss of elastic fibers in the superficial dermis (fig. 3) and the diagnosis was consistent with anetoderma. 
Direct immunofluorescence (DIF) was negative for IgA, IgG, IgM, C1q, C3 and fibrinogen. CBC, ESR, 
and routine chemistry were normal. The patient did not have any symptoms or show any sings of 
antiphospholipid syndrome (APS), and screening for antiphospholipid antibodies (anticardiolipin 
profile, anti-β-2-glycoprotein, IgG and IgM, and lupus anticoagulant) were all negative. Also, PT, PTT 
and INR were within normal range. RPR, VDRL, treponema pallidum antibodies were negative. 
Antinuclear antibody (ANA), ENA screen (SMB, SMD, RNP-70, and RNP-A, RNP-C, SSA/RO52, 
SSA/RO60, SSB/LA, CENP-B, SCL-70, JO-1, Ribosomal P and histones) were negative. Thyroid panel 
test showed normal free thyroxine and thyroid stimulating hormone, but the patient had a positive high 
titer of thyroid peroxidase antibody (anti-TPO antibody) >116 IU/ ml. Positive anti-TPO antibody is 
consistent with autoimmune thyroiditis.  
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Discussion 
There are numerous reports and studies that link primary anetoderma (PA) to lupus 
erythematosus, but the relation has not been clearly established [1–14]. Moreover, there 
are isolated repots of PA and autoimmune diseases like primary hypothyroidism [15], 
Grave’s disease [16], Addison’s disease [14], Sjogren’s syndrome [17], alopecia areata [18], 
vitiligo [14, 18, 19] and multiple sclerosis [20]. Now, there is a growing body of evidence 
to consider PA as a cutaneous sign of positive antiphospholipid antibodies with or 
without fulfilling the criteria of APS [16, 21–34]. In our case, there is a high titer of 
antithyroid peroxidase antibodies, which is consistent with autoimmune thyroiditis. This 
is in accordance with the work of Hodak et al. [16] who described a case of PA with 
Grave’s disease, positive lupus anticoagulant and autoimmune hemolysis. It is important 
to mention that Grave’s disease in the study of Hodak et al. [16] had started 5 years after 
the onset of the PA. In our study, there were no clinical signs or symptoms of thyroid 
disease at the time of diagnosis; also free thyroxine and thyroid stimulating hormone were 
in a normal range, but we have to take the short duration of onset of PA in our case into 
consideration. 
Also, Bergman et al. [15] described a case of primary hypothyroidism that developed 3 
years after the onset of anetoderma. From our point of view and the aforementioned 
literature we have to think of PA as a cutaneous sign of autoimmunity and patients 
should be examined and carefully tested for autoimmune diseases, especially for 
antiphospholipid antibodies, lupus erythematosus and also thyroid antibodies. Patients 
should also be followed up because associated autoimmune diseases may develop later in 
the course of the disease, maybe years after the onset of anetoderma. 
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Fig. 1. Multiple small circumscribed wrinkled sacs like lesions on the shoulders and upper back. 
 
 
 
Fig. 2. Minimal dermal perivascular chronic inflammatory cells infiltrate.  
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Fig. 3. Elastic stain (Verhoef-Van Gieson) showing loss of elastic fibers in the superficial dermis. 
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